195 related articles for article (PubMed ID: 1603565)
21. Localization of varicella around cutaneous leishmaniasis.
Siadat AH; Nilforoush Zadeh MA; Moradi SH; Baradaran EH
Indian J Dermatol Venereol Leprol; 2007; 73(2):124-6. PubMed ID: 17456925
[No Abstract] [Full Text] [Related]
22. Unusual manifestation of genital cutaneous leishmaniasis in an immunocompetent patient from São Paulo, Brazil: A case report.
Reis LC; Lindoso JAL; Celeste BJ; Braz LMA; Ramos-Sanchez EM; Yamashiro-Kanashiro EH; Goto H; Oyafuso LKM
Rev Soc Bras Med Trop; 2021; 54():e0514-2020. PubMed ID: 33759920
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Old World cutaneous leishmaniasis with intralesionally injected meglumine antimoniate using a Dermojet device.
Bogenrieder T; Lehn N; Landthaler M; Stolz W
Dermatology; 2003; 206(3):269-72. PubMed ID: 12673089
[TBL] [Abstract][Full Text] [Related]
24. Emergency initiative to reduce leishmaniasis in Afghanistan.
Querido J
Lancet Infect Dis; 2004 Oct; 4(10):599. PubMed ID: 15470762
[No Abstract] [Full Text] [Related]
25. Treatment of recurrent cutaneous Leishmaniasis.
Momeni AZ; Aminjavaheri M
Int J Dermatol; 1995 Feb; 34(2):129-33. PubMed ID: 7737774
[TBL] [Abstract][Full Text] [Related]
26. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
Layegh P; Khademi Z; Afzal Aghaee M; Moghiman T
J Pediatric Infect Dis Soc; 2015 Dec; 4(4):356-8. PubMed ID: 26582874
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of lupoid cutaneous leishmaniasis with glucantime and topical trichloroacetic acid (a case report).
Nilforoushzadeh MA; Sadeghian G; Jaffary F; Ziaei H; Shirani-Bidabad L; Mahzoni P
Korean J Parasitol; 2008 Sep; 46(3):175-7. PubMed ID: 18830058
[TBL] [Abstract][Full Text] [Related]
28. Evaluating the efficacy of allopurinol and meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Esfandiarpour I; Alavi A
Int J Dermatol; 2002 Aug; 41(8):521-4. PubMed ID: 12207774
[TBL] [Abstract][Full Text] [Related]
29. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis.
Arevalo I; Tulliano G; Quispe A; Spaeth G; Matlashewski G; Llanos-Cuentas A; Pollack H
Clin Infect Dis; 2007 Jun; 44(12):1549-54. PubMed ID: 17516397
[TBL] [Abstract][Full Text] [Related]
30. [Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate].
Rodrigues AM; Hueb M; Santos TA; Fontes CJ
Rev Soc Bras Med Trop; 2006; 39(2):139-45. PubMed ID: 16699638
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of cryotherapy versus intralesional meglumine antimoniate (glucantime) for treatment of cutaneous leishmaniasis in children.
Layegh P; Pezeshkpoor F; Soruri AH; Naviafar P; Moghiman T
Am J Trop Med Hyg; 2009 Feb; 80(2):172-5. PubMed ID: 19190206
[TBL] [Abstract][Full Text] [Related]
32. Disseminated cutaneous leishmaniasis: ulcerovegetative and ulcero-crusted lesions.
Sgarbi IM; Santos FD; Monteiro VE; Fonseca SN; Bernardes Filho F
Braz J Infect Dis; 2017; 21(2):201-202. PubMed ID: 28012931
[No Abstract] [Full Text] [Related]
33. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
[TBL] [Abstract][Full Text] [Related]
34. A strange infiltrative plaque on the face.
Guarneri C; Wollina U; Chokoeva A; Lotti TM; Tchernev G
Braz J Infect Dis; 2016; 20(2):214-5. PubMed ID: 26748228
[No Abstract] [Full Text] [Related]
35. Electrocardiographic Alterations Related to Intralesional Glucantime® Treatments: A Potentially Severe Adverse Event.
García Bracamonte B; Burillo Martínez S; Morales Raya C; Ortiz Romero P
Actas Dermosifiliogr; 2022; 113(7):742-744. PubMed ID: 35331726
[No Abstract] [Full Text] [Related]
36. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.
Krause G; Kroeger A
Clin Infect Dis; 1999 Aug; 29(2):466-7. PubMed ID: 10476776
[No Abstract] [Full Text] [Related]
37. Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults.
Layegh P; Rahsepar S; Rahsepar AA
Am J Trop Med Hyg; 2011 Apr; 84(4):539-42. PubMed ID: 21460006
[TBL] [Abstract][Full Text] [Related]
38. Multiple leg ulcers in a traveler.
Cardenas GA; Gonzalez-Serva A; Cohen C
Cleve Clin J Med; 2004 Feb; 71(2):109-12. PubMed ID: 14982193
[No Abstract] [Full Text] [Related]
39. Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.
Shazad B; Abbaszadeh B; Khamesipour A
Eur J Dermatol; 2005; 15(2):85-7. PubMed ID: 15757817
[TBL] [Abstract][Full Text] [Related]
40. Comparison Of Oral Dapsone With Intramuscular Meglumine Antimoniate In Cutaneous Leishmaniasis.
Ahmed N; Malik S; Tahir M; Rahman A; Fayyaz I; Raza N; Iftikhar N
J Ayub Med Coll Abbottabad; 2022; 34(4):802-806. PubMed ID: 36566403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
